News
02-01-2010, 07:00 PM
The approval was based on a study that showed that patients on a combination of the drugs went 35 weeks before a cancer progression compared to 13 weeks for women who got Femara alone.
More... (http://www.healthcentral.com/breast-cancer/news-461195-98.html)
More... (http://www.healthcentral.com/breast-cancer/news-461195-98.html)